Suicide Re Attempts in Young Adults After First Suicide Attempt : Socio-demographic, Clinical and Biological Correlates (SURAYA)

March 25, 2022 updated by: Hôpital le Vinatier

SURAYA : Suicide Re Attempts in Young Adults After First Suicide Attempt : Socio-demographic, Clinical and Biological Correlates

Suicide is the second leading cause of death among people aged 15 to 24 (WHO, 2014). After a first suicide attempt, the 18 to 25 years old would be very likely to repeat the act: 25 to 31% would make a new attempt in the following year (Christiansen et al, 2007).

Nevertheless the literature on this subject is not detailed. In this project, we hypothesize that young adults aged 18 to 25 who have made their first suicide attempt will repeat their act more frequently than younger or older populations. In addition, these young people would have identifiable risk factors (sociodemographic, clinical and biological) that differ from young people who do not enter this phenomenon.

Our main objective is to measure the rate of suicidal reiteration in a population of young adults aged 18 to 25 years.

Our secondary objectives are to identify sociodemographic, clinical and biological characteristics of a population of suicidal re attempt young people, to highlight potential risk factors

Study Overview

Status

Recruiting

Conditions

Detailed Description

Objectives:

  • Our main objective is to measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.
  • Our secondary objectives are to identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors. We will try to highlight correlations between the reiteration of the suicidal act and:

    1. socio-demographic criteria: level of urbanity, socio-economic level, social and family context, date and place of birth, religion, sexual orientation, name and contact details of the general practitioner, previous access to care
    2. scores on the scales of various psychiatric pathologies, existing or in formation (eg depression, anxiety disorders, psychosis)
    3. alterations at the peripheral level
  • on the stress response system: cortisolemia and capillary cortisol levels
  • on the total and mature serum BDNF

In addition, DNA and RNA genetic samples will be taken in order to constitute a biological collection for later research.

Type of study: This is an interventional research with minimal risks and constraints (2 ° study), multicenter prospective cohort.

Number of centers: 2 Suicide Prevention Center at the Le Vinatier Hospital Center and the Post Crisis Unit at the Edouard Herriot Hospital of the Hospices Civils de Lyon.

Description of the study / experimental plan:

This is a prospective cohort study that will be divided into two groups: "repeat suicide attempt" and "no repeat attempt"

Primary judgment criterion:

This is the occurrence of repeating a suicide attempt (over a period of 3 months after the initial attempt.

In this project, a suicide attempt is defined according to WHO criteria as "non-fatal suicidal behavior, self-inflicted injury with a desire to end one's life that does not lead to death".

Number of subjects:

Our study will include 200 patients at the Le Vinatier CH Suicide Prevention Center and the Post Crisis Unit at Edouard Herriot Hospital.

inclusion criteria: between the ages of 18 and 25

  • a first suicide attempt
  • Master French sufficient

Exclusion Criteria:

-Majors protected: under curatorship or under guardianship

Course of the study :

-Inclusion will take place immediately after the first suicide attempt at the Post Crisis Unit at Edouard Herriot Hospital and the Suicide Prevention Center.

An anamnestic collection of social and demographic data will be carried out: level of urbanity, professional activity, level of study, access to care, and previous care received, socio-economic level, social and family context (notably existing conflict with parents or love break-up). The patient's telephone number will be collected as well as the patient's psychiatric and addiction history, and the means used for the suicide attempt.

Different scales of assessments, by means of self-questionnaires, will be given to the patient and an investigator will provide the C-SSRS scale assessment for the suicidal risk severity. Finally a venous blood sample will be performed with a measure of total and mature serum BDNF and cortisolemia. Capillary cortisol will also be measured.

After obtaining the patient's consent, two blood samples (DNA and RNA) will be collected and stored at -80 degrees to create a biological collection for later research.

An orientation in the course of care will then be given to the subject who will receive the appropriate care as well as a phone call made by the Suicide Prevention Center.

-At 3 months: A phone call will be made to check the presence or absence of the main evaluation criterion: the repetition of a suicide attempt. In addition, the patient will be asked about life events during these three months and the care received since inclusion.

Benefits and risks of this study:

The expected benefits of this study are: a better understanding of the mechanisms underlying the recurrence of the suicidal act, which could allow an optimal patient management and an adapted orientation in the care network, this for a setting in place in the near future.

In addition, patients included in the study will benefit from follow-up.

The foreseeable risk is the SR that can lead to suicide. To minimize this risk, each patient included in this protocol will benefit from a clinical evaluation performed by a trained investigator. At the end of this evaluation, according to the observed suicidal risk, an orientation in the course of care will be proposed. Each patient will be informed of the different modalities of psychiatry consultations and how to challenge the network. In addition, all patients will receive a phone call from the Suicide Prevention Center.

No serious adverse effects that could be attributed to the project are expected as part of this research.

Indeed, the blood test is carried out systematically as part of a post-suicide treatment and no other invasive examination is scheduled. The only undesirable events that can occur after a venous blood collection are: a hematoma at the point of puncture, pain during the bite, vagal discomfort or rare cases of infectious risks. These risks are greatly minimized by means of sterile single-use equipment and qualified medical personnel, and can not be considered as a serious expected adverse effect.

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Aura
      • Bron, Aura, France, 69678 CEDEX
        • Recruiting
        • Centre Hospitalier Le Vinatier
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 25 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • between the ages of 18 and 25
  • a first suicide attempt
  • Master French sufficient

Exclusion Criteria:

  • Majors protected: under curatorship or under guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: SUICID ATTEMPT YOUNG PEOPLE
Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates

To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.

To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Assessment of the prevalence of SR rate over a 3-months period after the first suicide attempt, among young adults aged 18 to 25.
Time Frame: Within the first 3 months following a first suicide attempt
Within the first 3 months following a first suicide attempt

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mature and total BDNF
Time Frame: Within the first 3 months after the first suicide attempt
We will try to highlight correlations between the reiteration of the suicidal act and biological measures
Within the first 3 months after the first suicide attempt
level of urbanity
Time Frame: Within the first 3 month following a first suicide attempt
sociodemographic risk factor
Within the first 3 month following a first suicide attempt
socio-economic level
Time Frame: Within the first 3 month following a first suicide attempt
sociodemographic risk factor
Within the first 3 month following a first suicide attempt
social and family context
Time Frame: Within the first 3 months following a first suicide attempt
sociodemographic risk factor
Within the first 3 months following a first suicide attempt
date of birth
Time Frame: Within the first 3 months following a first suicide attempt
sociodemographic risk factor
Within the first 3 months following a first suicide attempt
place of birth
Time Frame: Within the first 3 months following a first suicide attempt
sociodemographic risk factor
Within the first 3 months following a first suicide attempt
BIS : Barratt Impulsive Scale
Time Frame: Within the first 3 months following a first suicide attempt

The Barratt Impulsiveness Scale (BIS) is a widely used measure of impulsiveness. It includes 30 items that are scored to yield six first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and three second-order factors (attentional, motor, and non-planning impulsiveness).

Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales

Within the first 3 months following a first suicide attempt
C-SSRS : Colombia Suicide Severity Rating Scale
Time Frame: Within the first 3 months following a first suicide attempt

The Screener contains 6 "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide over the past month and behaviors over their lifetime and past 3 months. Each question addresses a different component of the respondent's suicide ideation severity and behavior.

Question 1: wish to be dead Question 2: non-specific suicidal thoughts Questions 3-5: more specific suicidal thoughts and intent to act Question 6: suicidal behavior over the respondent's lifetime and past 3 months If the respondent answers "yes" to Question 2, he/she is instructed to answer Questions 3-5. If the respondent answers "no" to Question 2, he/she may skip to Question 6.

An answer of "yes" to any of the six questions may indicate a need for referral to a trained mental health professional and an answer of "yes" to questions 4, 5 or 6 indicate high-risk.

Within the first 3 months following a first suicide attempt
hair cortisol and blood cortisol
Time Frame: Within the first 3 months following a first suicide attempt
We will try to highlight correlations between the reiteration of the suicidal act and biological measures
Within the first 3 months following a first suicide attempt
Analog visual scales
Time Frame: Within the first 3 months following a first suicide attempt

The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales

Within the first 3 months following a first suicide attempt
Negative life events during the last 6 months
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
The reasons for living inventory
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
CTQ : childhood trauma questionnary
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
STAXI-2
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
PQB : psychosis risk screening
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
QIDS : Quick Inventory of Depressive Symptomatology
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
MDQ : Mood disorder questionnaire
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
CUDIT : Cannabis use Disorders Identification Test
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
CAST : Cannabis Abuse Screening Test
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
Fagerstrom Questionary
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt
AUDIT : Alcohol use disorders test
Time Frame: Within the first 3 months following a first suicide attempt
Clinical risk factor : We aim to highlight correlations between the reiteration of the suicidal act and different scores on clinical scales
Within the first 3 months following a first suicide attempt

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: POULET Emmanuel, Ph, CH Le Vinatier

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 22, 2018

Primary Completion (ANTICIPATED)

December 31, 2022

Study Completion (ANTICIPATED)

January 30, 2023

Study Registration Dates

First Submitted

April 16, 2018

First Submitted That Met QC Criteria

May 15, 2018

First Posted (ACTUAL)

May 29, 2018

Study Record Updates

Last Update Posted (ACTUAL)

March 28, 2022

Last Update Submitted That Met QC Criteria

March 25, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2017-A03129-44

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicide

Clinical Trials on clinical and biological correlates

3
Subscribe